mAbs

· ISSN (print) 1942-0862 · ISSN (e) 1942-0870 · 5 papers in corpus
2025
doi:10.1080/19420862.2025.2553624 ·PMID:40936197

Antibodies that bind in a pH-dependent manner to their antigens show promise for enhanced neutralization potency and blocking capacity against extracellular targets. However, because the mechanisms governing pH-dependent antigen binding rem…

2023
doi:10.1080/19420862.2023.2254676 ·PMID:37698877

Prolactin (PRL) has recently been demonstrated to elicit female-selective nociceptor sensitization and increase pain-like behaviors in female animals. Here we report the discovery and characterization of first-in-class, humanized PRL neutra…

2013
doi:10.4161/mabs.24105 ·PMID:23493119

The 8th European Antibody Congress (EAC), organized by Terrapin Ltd., was again held in Geneva, Switzerland, following on the tradition established with the 4th EAC. The new agenda format for 2012 included three parallel tracks on: (1) nake…

2013
doi:10.4161/mabs.23655 ·PMID:23575266

The 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences, and the 2012 Annual Meeting of The Antibody Society, organized by IBC Life Sciences with contributions from The Antibody Society and two Scie…

2012
doi:10.4161/mabs.21024 ·PMID:22820181

Peptibodies or peptide-Fc fusions are an attractive alternative therapeutic format to monoclonal antibodies. They consist of biologically active peptides grafted onto an Fc domain. This approach retains certain desirable features of antibod…